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The number of cancer patients in Europe is rising and significant advances in basic and applied cancer research are
making the provision of optimal care more challenging. The concept of cancer as a systemic, highly heterogeneous and
complex disease has increased the awareness that quality cancer care should be provided by a multidisciplinary team
(MDT) of highly qualified healthcare professionals. Cancer patients also have the right to benefit from medical progress by
receiving optimal treatment from adequately trained and highly skilled medical professionals. Built on the highest stan-
dards of professional training and continuing medical education, medical oncology is recognised as an independent
medical specialty in many European countries. Medical oncology is a core member of the MDT and offers cancer patients
a comprehensive and systemic approach to treatment and care, while ensuring evidence-based, safe and cost-effective
use of cancer drugs and preserving the quality of life of cancer patients through the entire ‘cancer journey’. Medical oncol-
ogists are also engaged in clinical and translational research to promote innovation and new therapies and they contribute
to cancer diagnosis, prevention and research, making a difference for patients in a dynamic, stimulating professional en-
vironment. Medical oncologists play an important role in shaping the future of healthcare through innovation and are also
actively involved at the political level to ensure a maximum contribution of the profession to Society and to tackle future
challenges. This position paper summarises the multifarious and vital contributions of medical oncology and medical
oncologists to today’s and tomorrow’s professional cancer care.
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The number of cancer patients in Europe is rising and signifi-
cant advances in basic and applied cancer research are making
the provision of optimal care more challenging. The concept of
cancer as a systemic, highly heterogeneous and complex disease
has increased the awareness that quality cancer care should be
provided by a multidisciplinary team (MDT) of highly qualified
healthcare professionals. Cancer patients also have the right to
benefit from medical progress by receiving optimal treatment
from adequately trained and highly skilled medical profes-
sionals. This position paper summarises the multifarious and
vital contributions of medical oncology and medical oncologists
to today’s and tomorrow’s professional cancer care.
Medical oncology is a core member of the MDT and offers
cancer patients a comprehensive and systemic approach to treat-
ment and care, spanning the entire disease spectrum, including
research, prevention, diagnosis, treatment, rehabilitation and
supportive and palliative care, thereby complementing the skill
sets of cancer specialists from other disciplines. Medical oncolo-
gists are trained in the comprehensive management of cancer
patients, the safe delivery of systemic cancer treatments and the
management of treatment side-effects and disease symptoms.
As part of their training and clinical practice, medical oncolo-
gists frequently engage in clinical and translational research to
promote innovation and new therapies.
an independent medical specialty
Historically a subspecialty of internal medicine, and established
in both North America and Europe in the 1960s, medical oncol-
ogy was formally recognised in the European Union (EU) as an
independent medical specialty and professional qualification in
March 2011, after many years of intense discussion between
ESMO, key national societies and EU Member States. The EU
recognition was an important step towards ensuring harmonisa-
tion of appropriate professional qualifications and free movement
of specialists across borders, promoting equal access to optimal
treatment and care for all cancer patients.
In light of the diversity of health systems and the status of
cancer care in Europe and around the world, but also because
medical oncology has yet to be recognised as a specialty in several
European countries (Figure 1), the ESMO/ASCO Recommendations
for a Global Curriculum in Medical Oncology provide a set of
guidelines ‘to be adopted by national educational and health
bodies according to the resources and conditions of their
country’ [2]. In this and many other fields related to the art,
science, recognition and practice of medical oncology, ESMO
highly encourages attempts ‘to establish coherency between
national standards and broader European ones’ [3].
building on the highest standards
of qualification
According to the ESMO/ASCO Recommendations for a Global
Curriculum in Medical Oncology, the training requirements in
medical oncology are a minimum of 5 years, beginning with at
least 2 years of training in internal medicine and followed by a
medical oncology training programme for a minimum of 2 years
that must include full-time clinical training in the diagnosis and
management of cancer patients and clinical experience of treat-
ments across the diverse range of neoplastic diseases. Experience
in cancer research for at least 1 year, including international train-
ing where appropriate, is also strongly recommended [2]. Medical
oncology professionals may also sub-specialise in a specific field
of care or disease area(s) that fall within their expertise.
As with other specialties, medical oncologists must participate
in continuing medical education (CME) programmes, whose
main objectives are ‘to improve the quality of patient care, set
standards of clinical competence for practice and encourage the
continuing scholarship required for professional excellence over
a lifetime of service’ [4, 5]. Insight into the complexity of oncol-
ogy and the necessity of multidisciplinary cancer care has to
start at medical school and extend to continuous education in
all stages of professional life. Medical oncologists play an im-
portant role in educating medical students and training young
doctors in oncology. In support of this and to promote the
highest standards of qualification of medical oncologists, ESMO
has a multidisciplinary faculty of over 300 leading oncology
experts and offers a full range of targeted information and edu-
cation programmes and services, including scientific meetings
and courses, publications, web portals and e-learning modules,
fellowships, a CME certification and recertification programme
and an annual ESMO Examination (http://www.esmo.org/
Science-Education).
partnering in multidisciplinary and
comprehensive cancer care
Oncology MDTs are an excellent tool for combining the expert-
ise and skills from different disciplines to develop optimal treat-
ment plans for cancer patients. Medical oncologists work as
core members of the integrated MDT and, where appropriate,
can serve as the ‘patient interface’, while collaborating with
primary care physicians, pathologists, imaging specialists, surgi-
cal oncologists, radiation oncologists, pharmacists, palliative
care experts, psycho-oncologists, as well as oncology nurses and
experts from other medical specialties. Medical oncologists have
a special qualification in the care for the increasing number of
co- and multimorbid patients and in the integration of their
needs in the MDT.
The composition of the MDT depends on the local availabil-
ity of qualified healthcare professionals in the region and the
practice setting, but the contribution of the medical oncologist
is essential to integrate all the information in the interest of the
patient, regardless of the setting. Cancer patients should also
have access to psychosocial, nutritional and other relevant coun-
selling services [6]. Moreover, they should be encouraged to
seek MDT review and evaluation of their case before proceeding
to appropriate therapy. Medical oncology is a core element in
establishing area-wide provision of cancer care in Europe and
contributes to avoiding coverage gaps between urban and rural
areas. In settings where regular and efficient face-to-face MDT
meetings are difficult to establish, telemedicine-delivered MDTs
may offer a suitable alternative [7].
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ensuring evidence-based, safe and
cost-effective use of cancer drugs and
preserving the quality of life of cancer
patients
Core competences of medical oncologists include dealing with a
steadily growing number of molecular-based cancer subtypes
and managing an increasing number of comorbidities and com-
bination therapies as well as related short- and long-term side-
effects. In treating cancer as a systemic disease and with the
knowledge across tumour types of when to use which medica-
tion or combination therapy and at what dose, as well as when it
is in the patient’s best interests to stop drug treatment, medical
oncologists are uniquely positioned to ensure that costly cancer
medicines are used in the safest, least toxic and most cost-effect-
ive way possible. ESMO offers more than 50 regularly updated
Clinical Practice Guidelines helping oncologists provide cancer
patients with evidence-based and state-of-the-art treatment
options (http://www.esmo.org/Guidelines-Practice/Clinical-Practice-
Guidelines).
Due to their comprehensive specialist training and patient-
centred holistic approach to quality cancer care that aims to
guide and support the patient through the entire ‘cancer
journey’, well-trained medical oncologists are also adequately
skilled in supportive, palliative and end-of-life care, as well as in
providing adequate information on lifestyle and late complica-
tions for cured patients. Preserving a cancer patient’s quality of
life in all phases of disease and after successful treatment also
includes continuously assessing the patient’s physical and psy-
chological symptoms and making sure that these problems are
fully recognised and adequately addressed. Where appropriate,
this is done in collaboration with experts of other medical and
non-medical disciplines [8]. Medical oncology is speaking medi-
cine. Continuous communications with patients and their rela-
tives is a prerequisite for decisions at all stages of disease. Medical
oncology is particularly suited to deliver guidance in challenging
Figure 1. Recognition of medical oncology as an independent medical specialty in Europe [1].
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situations. This also includes managing cancer in special life
situations (cancer in the elderly, in adolescents and young adults,
cancer during pregnancy, cancer in organ-transplanted patients
etc.) as well as maintaining long-term relationships with cancer
survivors and dealing with delayed sequellae or side-effects of
systemic therapies.
contributing to cancer diagnosis,
prevention and research
The increasing availability of molecular-based therapies means
that medical oncologists also have an enlarging role to play in
the appropriate use of molecular and companion diagnostics,
with a view to integrating these activities within tumour pathology
into the clinical setting and ensuring more accurate and specific
tumour characterization [9]. There is also broad consensus that
medical oncology professionals can and should contribute to lessen-
ing the cancer burden in society by helping reduce the incidence of
cancer (primary prevention), detecting cancer at an early stage
(through screening; secondary prevention) and preventing locore-
gional relapse and/or metastatic disease after primary surgical or
radiotherapy treatment (tertiary prevention) [10].
Working in the fast-evolving field of oncology, the active par-
ticipation in clinical and translational research constitutes
another key characteristic of a medical oncologist. A solid
understanding of the ‘proper conduct and interpretation of
translational and clinical research’ is a standard requirement for
successful training in medical oncology [2]. Future cancer re-
search will increasingly depend on the ability to organise in-
novative clinical trials via regional, national or international
networks, making sure that uncommon cancers and rare sub-
types of more common cancers sharing a specific molecular
profile can be successfully identified and included. Adequate
funding, appropriate organisational, regulatory and Information
Technology (IT) infrastructures and broad public support are
essential requirements for this to happen to the benefit of cancer
patients.
making a difference for patients in
a dynamic, stimulating professional
environment
Medical oncology is a highly demanding but also very meaning-
ful and rewarding profession that involves close and often long-
term interactions with cancer patients, with the opportunity and
responsibility to have a fundamental impact on their lives.
Medical oncology also offers a broad diversity of activities, in-
cluding multidisciplinary collaboration and involvement in clin-
ical and translational research. Building on an excellent
education and on a position at the centre of cancer care, young
medical oncologists have a wide variety of exciting professional
career opportunities to choose from in public, academic, private
or industry practice [11].
In clinical practice, medical oncologists are dealing with an
increasing number of treatment options for a growing number
of cancers and cancer patients whilst continuously striving to
keep themselves and their patients abreast of the latest develop-
ments in the rapidly advancing field of oncology. At the same
time, through their involvement in research, medical oncologists
are key drivers of medical innovation. Since the beginning of the
chemotherapy era in the 1940s, medical oncology has contribu-
ted probably more than any other medical discipline to the de-
velopment and use of novel cancer treatment options.
shaping the future of healthcare
through innovation
A better understanding of cancer biology and signalling path-
ways has helped to define a growing number of cancer subsets
and has led to the development of targeted therapies for some
cancers. The paradigm of cancer care is continuously shifting
from treating a single, homogeneous and organ-based disease to
confronting a highly complex, heterogeneous and constantly
changing group of molecular-based diseases that can occur sim-
ultaneously or evolve in the same organ or anywhere in the
body. This has a significant impact on the practice of cancer
care and has promoted the medical oncology profession into a
pole position for innovation in cancer medicine.
New imaging and eHealth-based technologies, molecular and
companion diagnostics, multiplex testing and next-generation
sequencing will increasingly allow for a better ‘personalisation’
of cancer care, identifying those patients who are most likely to
benefit from a specific intervention while sparing them poten-
tially high levels of toxicity and side-effects/adverse events and
avoiding unnecessary treatment cost. Medical oncologists are at
the core of this development and already screening for HER2
overexpression/amplification in breast cancer, RAS mutations in
colorectal cancer and EGFR mutations or ALK translocation in
lung cancer is becoming standard practice and exemplifies some
of the progress made in the ‘personalised’ treatment of these
three common cancers.
actively involved at the political level
However, a lot remains to be done and future progress in ‘perso-
nalised’ cancer care will require not only multidisciplinarity and
more flexible regulatory frameworks but also powerful IT-based
tools for knowledge generation, management and dissemin-
ation. By actively engaging in health and research policy at na-
tional and European levels, medical oncologists and their
specialist organisations such as ESMO can contribute to making
sure that all cancer patients in Europe will have equal access to
novel and standard diagnostic procedures, appropriate cancer
medicines and high-quality palliative care services. This lobby-
ing should also include the provision of adequate national ap-
proval and reimbursement systems and drug supplies, including
the participation of oncology experts in risk–benefit assessment
of new drugs and the definition of indispensable drugs, and
drive improvements and harmonisation of national policies gov-
erning the off-label use of drugs, which is common practice in
oncology [12].
In this context, it is crucial to advocate for the formal recogni-
tion of medical oncology as an independent medical specialty in
countries where this is still not the case, and also for the har-
monisation of professional qualifications in Europe. Potential
future workforce shortages are furthermore high on the political
 | Popescu et al. Volume 25 | No. 1 | January 2014
special article Annals of Oncology
Downloaded from https://academic.oup.com/annonc/article-abstract/25/1/9/166306
by guest
on 19 March 2018
agenda in some European countries. Other political issues
include the need to further improve the environment for bench-
to-bedside research and rapid, collaborative assessment through
innovative (and more flexible) clinical trials of novel therapeutic
interventions. ESMO is actively involved in many political
initiatives at the European level and is fully committed to
synthesising national experience and professional concerns into
‘common’ policy recommendations.
contributing to society and ready
for the future
Due to increasing life expectancy, more members of our society
will be affected by cancer during their lifetimes. Faced with an
increasing number of cancer patients, medical oncologists, in
partnership with professionals from other disciplines, are
working very hard to continuously provide evidence-based
quality cancer care while striving to further accelerate medical
progress for the benefit of each individual patient. Where cure is
not possible, the aim is to turn cancer into a ‘chronic’ disease
with a tumour burden as low as possible, allowing many patients
to lead full and active lives.
Oncology is going to change dramatically over the coming
years and new IT and health technologies will further increase
the ability to tailor cancer therapies to specific molecular patient
profiles and to provide a more ‘personalised’ cancer care. To
confront the growing cancer burden in Europe and worldwide,
greater strategic and financial investments are necessary in the
fields of cancer prevention, screening, research, health technol-
ogy development (and availability) and multidisciplinary care as
well as in knowledge dissemination to professionals and
patients. In working together with all disciplines involved in on-
cology, the specialty of medical oncology supported by ESMO
and the many national societies are well positioned to accept
these challenges and make sure that cancer patients receive the
best treatment possible from highly skilled, well-trained and
continuously educated top-quality oncology professionals. This
will benefit cancer patients and the society as a whole.
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